Sign In
Buy CTMX
$3.22
+0.0600 (+1.90%)
At Close: Jun 03, 2026
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
04:02pm, Thursday, 07'th Jul 2022 Benzinga
Gainers
United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
American
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades
For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
This Analyst Cuts Price Target On Microsoft; Here's The Biggest Price Target Changes For Thursday
11:53am, Thursday, 07'th Jul 2022 Benzinga
Truist Securities cut Criteo S.A. (NASDAQ: CRTO) price target from $40 to $35. Criteo shares fell 3.5% to close at $22.92 on Wednesday.
Barclays raised Eli Lilly and Company (NYSE: LLY) price targ
Why Is GameStop Surging By Around 10%? 22 Stocks Moving In Thursday's Pre-Market Session
10:25am, Thursday, 07'th Jul 2022 Benzinga
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 39.6% to $0.2471 in pre-market trading after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special
U.S. Stock Futures Edge Higher After Fed Minutes
09:07am, Thursday, 07'th Jul 2022 Benzinga
Pre-open movers
U.S. stock futures traded slightly higher in early pre-market trade on Thursday following the release of Wednesday’s Fed meeting minutes, suggesting inflation remains the central ban
CytomX's Breast Cancer Candidate Meets Primary Goal Of Objective Response Rate
06:32am, Thursday, 07'th Jul 2022
CytomX Therapeutics Inc's (NASDAQ: CTMX) Phase 2 study of praluzatamab ravtansine in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
08:05pm, Wednesday, 06'th Jul 2022 GlobeNewswire Inc.
- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer -
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
12:33pm, Monday, 27'th Jun 2022 Zacks Investment Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
08:00am, Wednesday, 01'st Jun 2022
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q1 2022 Results - Earnings Call Transcript
03:17pm, Saturday, 07'th May 2022
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Chau Cheng - VP, IR & Corporate Communications Sean McCarthy - CEO & Chairman Amy
CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript
02:30am, Saturday, 07'th May 2022 The Motley Fool
CTMX earnings call for the period ending March 31, 2022.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
10:25pm, Thursday, 05'th May 2022 Zacks Investment Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
08:15pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 -
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
12:00pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
08:00am, Thursday, 28'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that i
